Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
PER Pulse™ Recap
This first of 3 PER Pulse™ Recaps highlights key points presented in Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Posttransplant Obstacles..
Diagnosis of and Risk Factors for Veno-Occlusive Disease
Pediatric hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is an ominous complication of hematopoietic stem cell transplantation (HSCT). The development of VOD is associated with patient morbidity, and can progress to become life-threatening in approximately 30% to 50% of cases.1 The severe form of VOD, which is associated with multiorgan dysfunction, may carry a mortality rate of greater than 80%.2 Current diagnostic and management approaches for VOD in the pediatric population are highly variable in clinical practice.3 As diagnostic and management approaches for VOD continue to evolve, awareness of new evidence and clinical guidelines may help to optimize outcomes for patients undergoing HSCT. Dr Stephan Grupp, director of the Cancer Immunotherapy Frontier Program and CCCR director of Translational Research at Children's Hospital of Philadelphia, provides his insights on current and evolving diagnostic approaches for VOD. He also shares his perspectives on patient- and disease-related risk factors for the development of VOD following transplant, including risk factors specific to the pediatric population, such as low weight, age younger than 1 to 2 years, being treated for neuroblastoma, and being treated for nonmalignant conditions such as hemophagocytic lymphohistiocytosis or osteopetrosis. This segment will also address evidence pertaining to the use of different imaging techniques in the diagnosis of VOD.4-7
This second of 3 PER Pulse™ Recaps highlights key points presented in Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Posttransplant Obstacles.
VOD Risk Stratification and Data Pertaining to the Use of Prophylaxis
Severe VOD is established with the emergence of multiorgan failure, which carries a mortality rate that may exceed 80%. Preclinical assessment has shown that defibrotide has a protective effect on endothelial cells. It also affects endothelial cells by reducing their procoagulant activity and increasing their fibrinolytic properties.1 These preclinical data and other early clinical studies led to the development of a phase III, open-label, randomized, controlled trial of defibrotide for prophylaxis of VOD in pediatric patients who had undergone myeloablative conditioning before HSCT. These patients were noted to have at least 1 risk factor for VOD. Patients who received defibrotide prophylaxis had a lower incidence of VOD by day 30 post-HSCT relative to those who received best supportive care (12% vs 20%; P =.0507, log-rank test; P =.0488, Z test for competing risk analysis).1 Dr Grupp shares his insights on these data, as well as ongoing investigation into the potential of defibrotide for VOD prophylaxis,2 as well as other agents that have been studied for prophylaxis of VOD, including ursodeoxycholic acid and antithrombin III.3
3 of 3
PER Pulse™ Recap
This third of 3 PER Pulse™ Recaps highlights key points presented in Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Posttransplant Obstacles.
Treatment Approaches and Counseling Strategies for Patients With VOD
A key phase III trial of defibrotide for the treatment of patients with severe VOD and multi-organ failure used a historical control arm methodology for ethical reasons to assess the influence of defibrotide on day 100-plus post-HSCT survival.1 A 23 % improvement in survival was noted, with hypotension being the most common adverse event (AE) in both groups. No difference in common hemorrhagic AEs was observed.1
Prior to its approval in the United States for the treatment of VOD with renal or pulmonary dysfunction following HSCT, defibrotide was made available through a treatment protocol study of patients who had VOD with or without multiorgan failure.2 Interim results from this study showed that 50.3% of patients were alive at Day+100 post-HSCT. In the pediatric (≤16 years old) subgroup, 54.5% of patients were alive at day 100, while 44.9% of adult patients were alive at day 100.2 For patients with multiorgan failure, 45.3% were alive at day 100. Hypotension was the most commonly reported treatment-related AE.2
Dr Grupp provides his assessment of these studies pertaining to the use of defibrotide in patients with VOD. He also addresses data pertaining to the timing of treatment initiation, adverse events seen with the use of defibrotide, and counseling strategies for patients who may be candidates for this treatment option. He also provides commentary on other options that have been used in the treatment of VOD, such as methylprednisolone,3 as well as supportive care measures for patients with VOD.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY